Home Newsfeeds Baird Downgrades SPS Commerce to Neutral, Announces $151 Price Target

Baird Downgrades SPS Commerce to Neutral, Announces $151 Price Target

Baird analyst Joe Vruwink downgrades SPS Commerce (NASDAQ:SPSC) from Outperform to Neutral and announces $151 price target.

byBenzinga Newsdesk

December 14, 2022

1 minute read

Baird analyst Joe Vruwink downgrades SPS Commerce (NASDAQ:SPSC) from Outperform to Neutral and announces $151 price target.

Automation Anywhere Secures $200M In Financing From Silicon Valley Bank And Hercules Capital

By Benzinga Newsdesk

October 3, 9:41 AM

SAN JOSE, Calif., Oct. 3, 2022 /PRNewswire/ -- Automation Anywhere, Inc. , a global leader in Robotic Process Automation (RPA), announced today that it is has secured $200 million in

HTGC

Barclays Maintains Overweight on Cintas, Raises Price Target to $500

By Benzinga Newsdesk

December 2, 8:10 AM

Barclays analyst Manav Patnaik maintains Cintas (NASDAQ:CTAS) with a Overweight and raises the price target from $435 to $500.

CTAS

Analyst Ratings

Expert Ratings for Plains All American

By Benzinga Insights

November 6, 5:00 PM

Within the last quarter, Plains All American (NASDAQ:PAA) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent…

PAA

FDA Grants Orphan Designation For Lipella’s LP-310 Drug Candidate For Oral Graft-Versus-Host Disease

By Benzinga Newsdesk

November 10, 9:03 AM

Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host disease Lipella

LIPO

Baird Downgrades SPS Commerce to Neutral, Announces $151 Price Target

Related Posts

Automation Anywhere Secures $200M In Financing From Silicon Valley Bank And Hercules Capital

Barclays Maintains Overweight on Cintas, Raises Price Target to $500

Expert Ratings for Plains All American

FDA Grants Orphan Designation For Lipella’s LP-310 Drug Candidate For Oral Graft-Versus-Host Disease